Nirvanol

Nirvanol
Clinical data
Other names	5-Ethyl-5-phenylhydantoin
Routes of; administration	By mouth[1]
ATC code	None;
Identifiers
	IUPAC name 5-Ethyl-5-phenylimidazolidine-2,4-dione;
CAS Number	631-07-2;
PubChem CID	91480;
ChemSpider	82605;
UNII	23SM1FA1AK;
CompTox Dashboard (EPA)	DTXSID80874185 ;
ECHA InfoCard	100.010.138
Chemical and physical data
Formula	C11H12N2O2
Molar mass	204.22518 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1(C(=O)NC(=O)N1)C2=CC=CC=C2;
	InChI InChI=InChI=1S/C11H12N2O2/c1-2-11(8-6-4-3-5-7-8)9(14)12-10(15)13-11/h3-7H,2H2,1H3,(H2,12,13,14,15); Key:UDTWZFJEMMUFLC-UHFFFAOYSA-N;

Nirvanol, also known as ethylphenylhydantoin, is a derivative of hydantoin with anticonvulsant properties. Its 5-ethyl-5-phenyl substitution pattern is similar to that of phenobarbital.[2] It is useful in the treatment of chorea.[3]

Metabolism

Metabolism of nirvanol is stereoselective, with the (S)- enantiomer undergoing roughly 14 times more hydroxylation at the 4 position of the phenyl group than the (R)-enantiomer.[4][5]

gollark: If they did in fact mean it as a DSL for deploying bees against Google Cloud, they should say so.

gollark: I mean, I did say "treated as a general purpose language" so it's fairly reasonable.

gollark: It does not say "but only if all you do is interface docker to HTTP to bees" or something.

gollark: > Go is an open source programming language that makes it easy to build simple, reliable, and efficient software.

gollark: Yes it is. Generally, it is nice if you don't have to just completely switch languages for some types of problem, in what is treated/marketed as a general purpose language.

References

Theodore WH, Newmark ME, Desai BT, Kupferberg HJ, Penry JK, Porter RJ, Yonekawa WD (August 1984). "Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients". Neurology. 34 (8): 1100–2. doi:10.1212/wnl.34.8.1100. PMID 6431315.
Read WT (August 1922). "Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin (nirvanol)". J. Am. Chem. Soc. 44 (8): 1746–55. doi:10.1021/ja01429a017.
Ashby HT (February 1930). "Treatment of Chorea by Nirvanol". Archives of Disease in Childhood. 5 (25): 42–3. doi:10.1136/adc.5.25.42. PMC 1975064. PMID 21031794.
Küpfer A, Patwardhan R, Ward S, Schenker S, Preisig R, Branch RA (July 1984). "Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 28–33. PMID 6747829.
Butler TC (November 1953). "Quantitative studies of the physiological disposition of 3-methyl-5-ethyl-5-phenyl hydantoin (mesantoin) and 5-ethyl-5-phenyl hydantoin (nirvanol)". The Journal of Pharmacology and Experimental Therapeutics. 109 (3): 340–5. PMID 13109695.

External links

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Theodore1984-1] Theodore WH, Newmark ME, Desai BT, Kupferberg HJ, Penry JK, Porter RJ, Yonekawa WD (August 1984). "Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients". Neurology. 34 (8): 1100–2. doi:10.1212/wnl.34.8.1100. PMID 6431315.

[Read1922-2] Read WT (August 1922). "Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin (nirvanol)". J. Am. Chem. Soc. 44 (8): 1746–55. doi:10.1021/ja01429a017.

[Ashby1930-3] Ashby HT (February 1930). "Treatment of Chorea by Nirvanol". Archives of Disease in Childhood. 5 (25): 42–3. doi:10.1136/adc.5.25.42. PMC 1975064. PMID 21031794.

[Kupfer1984-4] Küpfer A, Patwardhan R, Ward S, Schenker S, Preisig R, Branch RA (July 1984). "Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 28–33. PMID 6747829.

[Butler1953-5] Butler TC (November 1953). "Quantitative studies of the physiological disposition of 3-methyl-5-ethyl-5-phenyl hydantoin (mesantoin) and 5-ethyl-5-phenyl hydantoin (nirvanol)". The Journal of Pharmacology and Experimental Therapeutics. 109 (3): 340–5. PMID 13109695.